Adenosine triphosphate-based chemotherapy response assay predicts long-Term survival of primary epithelial ovarian cancer

Lan Ying Li, Sang Wun Kim, Eun Ji Nam, Jungyun Lee, Sunghoon Kim, Young Tae Kim

Research output: Contribution to journalArticle

Abstract

Objective The aim of this study is to analyze the long-Term relapse-free survival and overall survival outcomes of primary ovarian cancer patients using adenosine triphosphate-based chemotherapy response analysis. Methods In total, 162 primary epithelial ovarian cancer patients who underwent chemotherapy response assay for carboplatin, cisplatin, and paclitaxel by adenosine triphosphate-based chemotherapy response analysis prior to chemotherapy between December 2006 and November 2016 were retrospectively reviewed. Chemosensitivity with single or combined three agents and clinical characteristics of patients were studied to understand their correlation with long-Term relapse-free survival and overall survival. Results Median follow-up time was 61.4 (range 1-130) months. Univariate analysis showed the paclitaxel-sensitive group (HR = 0.625, 95%CI = 0.393 to 0.994), combined carboplatin and paclitaxel-sensitive group (HR = 0.574, 95%CI = 0.352 to 0.937), and combined carboplatin, cisplatin, and paclitaxel-sensitive group (HR = 0.489, 95%CI = 0.295 to 0.810) were highly associated with better relapse-free survival than their corresponding non-sensitive groups. The carboplatin-sensitive group (HR = 0.533, 95%CI = 0.303 to 0.939), cisplatin-sensitive group (HR = 0.433. 95%CI = 0.251 to 0.748), and combined carboplatin-and cisplatin-sensitive group (HR = 0.286, 95%CI = 0.142 to 0.576) were highly associated with better overall survival than their corresponding non-sensitive groups. Combined carboplatin, cisplatin, and paclitaxel chemosensitivity, together with International Federation of Gynecology and Obstetrics (FIGO) stage were independent predictors for relapse-free survival. Single or combined chemosensitivity of cisplatin and/or carboplatin, together with residual tumor size and FIGO stage, were significant independent predictors for overall survival on a multivariate hazard model. Conclusion Paclitaxel sensitivity is a prognostic factor of long-Term relapse-free survival in patients with epithelial ovarian cancer, but platinum sensitivity is a more important prognostic factor for long-Term overall survival.

Original languageEnglish
Pages (from-to)334-340
Number of pages7
JournalInternational Journal of Gynecological Cancer
Volume29
Issue number2
DOIs
Publication statusPublished - 2019 Feb 1

Fingerprint

Carboplatin
Adenosine Triphosphate
Drug Therapy
Survival
Recurrence
Paclitaxel
Cisplatin
Gynecology
Obstetrics
Ovarian epithelial cancer
Residual Neoplasm
Platinum
Proportional Hazards Models
Ovarian Neoplasms
TP protocol

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

@article{db84888e6238466a890b55679dff4558,
title = "Adenosine triphosphate-based chemotherapy response assay predicts long-Term survival of primary epithelial ovarian cancer",
abstract = "Objective The aim of this study is to analyze the long-Term relapse-free survival and overall survival outcomes of primary ovarian cancer patients using adenosine triphosphate-based chemotherapy response analysis. Methods In total, 162 primary epithelial ovarian cancer patients who underwent chemotherapy response assay for carboplatin, cisplatin, and paclitaxel by adenosine triphosphate-based chemotherapy response analysis prior to chemotherapy between December 2006 and November 2016 were retrospectively reviewed. Chemosensitivity with single or combined three agents and clinical characteristics of patients were studied to understand their correlation with long-Term relapse-free survival and overall survival. Results Median follow-up time was 61.4 (range 1-130) months. Univariate analysis showed the paclitaxel-sensitive group (HR = 0.625, 95{\%}CI = 0.393 to 0.994), combined carboplatin and paclitaxel-sensitive group (HR = 0.574, 95{\%}CI = 0.352 to 0.937), and combined carboplatin, cisplatin, and paclitaxel-sensitive group (HR = 0.489, 95{\%}CI = 0.295 to 0.810) were highly associated with better relapse-free survival than their corresponding non-sensitive groups. The carboplatin-sensitive group (HR = 0.533, 95{\%}CI = 0.303 to 0.939), cisplatin-sensitive group (HR = 0.433. 95{\%}CI = 0.251 to 0.748), and combined carboplatin-and cisplatin-sensitive group (HR = 0.286, 95{\%}CI = 0.142 to 0.576) were highly associated with better overall survival than their corresponding non-sensitive groups. Combined carboplatin, cisplatin, and paclitaxel chemosensitivity, together with International Federation of Gynecology and Obstetrics (FIGO) stage were independent predictors for relapse-free survival. Single or combined chemosensitivity of cisplatin and/or carboplatin, together with residual tumor size and FIGO stage, were significant independent predictors for overall survival on a multivariate hazard model. Conclusion Paclitaxel sensitivity is a prognostic factor of long-Term relapse-free survival in patients with epithelial ovarian cancer, but platinum sensitivity is a more important prognostic factor for long-Term overall survival.",
author = "Li, {Lan Ying} and Kim, {Sang Wun} and Nam, {Eun Ji} and Jungyun Lee and Sunghoon Kim and Kim, {Young Tae}",
year = "2019",
month = "2",
day = "1",
doi = "10.1136/ijgc-2018-000058",
language = "English",
volume = "29",
pages = "334--340",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Adenosine triphosphate-based chemotherapy response assay predicts long-Term survival of primary epithelial ovarian cancer. / Li, Lan Ying; Kim, Sang Wun; Nam, Eun Ji; Lee, Jungyun; Kim, Sunghoon; Kim, Young Tae.

In: International Journal of Gynecological Cancer, Vol. 29, No. 2, 01.02.2019, p. 334-340.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adenosine triphosphate-based chemotherapy response assay predicts long-Term survival of primary epithelial ovarian cancer

AU - Li, Lan Ying

AU - Kim, Sang Wun

AU - Nam, Eun Ji

AU - Lee, Jungyun

AU - Kim, Sunghoon

AU - Kim, Young Tae

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Objective The aim of this study is to analyze the long-Term relapse-free survival and overall survival outcomes of primary ovarian cancer patients using adenosine triphosphate-based chemotherapy response analysis. Methods In total, 162 primary epithelial ovarian cancer patients who underwent chemotherapy response assay for carboplatin, cisplatin, and paclitaxel by adenosine triphosphate-based chemotherapy response analysis prior to chemotherapy between December 2006 and November 2016 were retrospectively reviewed. Chemosensitivity with single or combined three agents and clinical characteristics of patients were studied to understand their correlation with long-Term relapse-free survival and overall survival. Results Median follow-up time was 61.4 (range 1-130) months. Univariate analysis showed the paclitaxel-sensitive group (HR = 0.625, 95%CI = 0.393 to 0.994), combined carboplatin and paclitaxel-sensitive group (HR = 0.574, 95%CI = 0.352 to 0.937), and combined carboplatin, cisplatin, and paclitaxel-sensitive group (HR = 0.489, 95%CI = 0.295 to 0.810) were highly associated with better relapse-free survival than their corresponding non-sensitive groups. The carboplatin-sensitive group (HR = 0.533, 95%CI = 0.303 to 0.939), cisplatin-sensitive group (HR = 0.433. 95%CI = 0.251 to 0.748), and combined carboplatin-and cisplatin-sensitive group (HR = 0.286, 95%CI = 0.142 to 0.576) were highly associated with better overall survival than their corresponding non-sensitive groups. Combined carboplatin, cisplatin, and paclitaxel chemosensitivity, together with International Federation of Gynecology and Obstetrics (FIGO) stage were independent predictors for relapse-free survival. Single or combined chemosensitivity of cisplatin and/or carboplatin, together with residual tumor size and FIGO stage, were significant independent predictors for overall survival on a multivariate hazard model. Conclusion Paclitaxel sensitivity is a prognostic factor of long-Term relapse-free survival in patients with epithelial ovarian cancer, but platinum sensitivity is a more important prognostic factor for long-Term overall survival.

AB - Objective The aim of this study is to analyze the long-Term relapse-free survival and overall survival outcomes of primary ovarian cancer patients using adenosine triphosphate-based chemotherapy response analysis. Methods In total, 162 primary epithelial ovarian cancer patients who underwent chemotherapy response assay for carboplatin, cisplatin, and paclitaxel by adenosine triphosphate-based chemotherapy response analysis prior to chemotherapy between December 2006 and November 2016 were retrospectively reviewed. Chemosensitivity with single or combined three agents and clinical characteristics of patients were studied to understand their correlation with long-Term relapse-free survival and overall survival. Results Median follow-up time was 61.4 (range 1-130) months. Univariate analysis showed the paclitaxel-sensitive group (HR = 0.625, 95%CI = 0.393 to 0.994), combined carboplatin and paclitaxel-sensitive group (HR = 0.574, 95%CI = 0.352 to 0.937), and combined carboplatin, cisplatin, and paclitaxel-sensitive group (HR = 0.489, 95%CI = 0.295 to 0.810) were highly associated with better relapse-free survival than their corresponding non-sensitive groups. The carboplatin-sensitive group (HR = 0.533, 95%CI = 0.303 to 0.939), cisplatin-sensitive group (HR = 0.433. 95%CI = 0.251 to 0.748), and combined carboplatin-and cisplatin-sensitive group (HR = 0.286, 95%CI = 0.142 to 0.576) were highly associated with better overall survival than their corresponding non-sensitive groups. Combined carboplatin, cisplatin, and paclitaxel chemosensitivity, together with International Federation of Gynecology and Obstetrics (FIGO) stage were independent predictors for relapse-free survival. Single or combined chemosensitivity of cisplatin and/or carboplatin, together with residual tumor size and FIGO stage, were significant independent predictors for overall survival on a multivariate hazard model. Conclusion Paclitaxel sensitivity is a prognostic factor of long-Term relapse-free survival in patients with epithelial ovarian cancer, but platinum sensitivity is a more important prognostic factor for long-Term overall survival.

UR - http://www.scopus.com/inward/record.url?scp=85061048157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061048157&partnerID=8YFLogxK

U2 - 10.1136/ijgc-2018-000058

DO - 10.1136/ijgc-2018-000058

M3 - Article

C2 - 30718314

AN - SCOPUS:85061048157

VL - 29

SP - 334

EP - 340

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 2

ER -